Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

This article was originally published in The Tan Sheet

Executive Summary

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Related Content

Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
FDA-FTC Collaboration Relies On Joint Enforcement, Not Single Agency Acts
Timely 483 Response Can Ease Agency Enforcement Action – FDA Official
FDA, FTC team up on STD warning letter
FDA issues H1N1 warning letters
FTC Enforcement Targets Probiotic Products, Spanish Language Advertising
FTC Prioritizes Food Advertising Investigations Over Supplement Claims
FTC's Pending Claim Substantiation Changes Will Weigh On Small Firms
Industry targets bogus H1N1 claims
Skinvisible Pharmaceuticals' sanitizer kills most H1N1





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts